This is to inform that due to some circumstances beyond the organizer control, “2nd Edition of International Conference on Gastroenterology” (Gastro 2024) during October 21-23, 2024 at Baltimore, MD, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at gastroenterology@magnusconference.com or call + 1 (702) 988-2320.
Portal hypertension is a medical condition characterized by increased blood pressure in the portal vein, which carries blood from the digestive organs to the liver. It is usually caused by liver disease or blockage of the portal vein, or both. The most common cause is cirrhosis, a condition in which scar tissue replaces healthy liver tissue. This scar tissue blocks the flow of blood through the liver, resulting in increased pressure in the portal vein. The most common symptom of portal hypertension is the enlargement of veins in the esophagus and stomach. These veins, known as esophageal and gastric varices, can rupture, leading to life-threatening bleeding. Other symptoms may include abdominal pain, nausea, vomiting, loss of appetite, and fatigue. Treatment for portal hypertension is aimed at reducing the pressure in the portal vein. This can be done by decreasing the amount of fluid in the portal vein, or by widening the vein. Medications such as beta-blockers, nitrates, and non-steroidal anti-inflammatory drugs (NSAIDs) may be used to reduce the pressure in the portal vein. In some cases, surgery may be necessary to remove blockages or to widen the vein.
Title : Novel exosomal biomarkers for MASH
Aleksandra Leszczynska, University of California San Diego, United States
Title : Validation of GLAS (GP73+LG2m+Age+Sex) and ASAP (Age+Sex+AFP+PIVKA-II) algorithms for the management of liver fibrosis, cirrhosis and cancer
Philip M Hemken, Abbott Diagnostics Division R&D, United States
Title : Reverse multiple myeloma: First hepatic amyloidosis then multiple myeloma
Milaris M Sanchez Cordero, Mayaguez Medical Center, Puerto Rico
Title : Autophagy promotes the survival of adipose mesenchymal stem/stromal cells and enhances their therapeutic effects in cisplatin-induced liver injury via modulating TGF-1/Smad and PI3K/AKT signaling pathways
Eman Mohamad EL Nashar, King Khalid University, Saudi Arabia
Title : Epigastric Impedance measures gastric malfunction non-invasively. Time to revive it
John Andrew Sutton, Gastria Ltd, United Kingdom
Title : Digesting the connection: Exploring the psychological impact of gastroenterology issues on mental and emotional well being
Tracy E Hill, MGS Products LLC, United States